Welcome to our dedicated page for Moolec Science news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science stock.
Moolec Science SA (NASDAQ: MLEC) generates news at the intersection of food-tech, life sciences, and agricultural biotechnology. The company regularly issues updates on how it engineers plants and microbes to produce animal proteins, nutritional oils, bioactive compounds, and biological inputs for regenerative agriculture through its Molecular Farming and precision fermentation platforms.
News about Moolec often covers progress in its key ingredient programs, such as its GLASO safflower technology enriched in gamma-linolenic acid and its Piggy Sooy™ soybean platform engineered to express porcine hemeproteins. Press releases have highlighted regulatory approvals, including feed and food approval for GLASO technology in Argentina and U.S. regulatory milestones for Piggy Sooy™, as well as large-scale agricultural campaigns and acreage expansion in the United States.
Investors and industry observers can also find coverage of Moolec’s corporate and strategic developments. Recent announcements include the closing of a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, which expanded Moolec’s activities into ag-biologicals, biomaterials, and R&D services. The company also reports on the integration of Mycofood™, its fungal-based alternative protein platform produced via precision fermentation.
Moolec’s news flow additionally includes capital markets and compliance updates, such as Nasdaq determination letters related to minimum bid price, stockholders’ equity, and filing timelines, as well as share consolidations and reverse stock splits intended to support continued listing on the Nasdaq Capital Market. For readers tracking MLEC, this news page provides a centralized view of operational milestones, regulatory events, strategic transactions, and listing-related actions that shape the company’s trajectory in the food-tech and life sciences sectors.
Moolec Science (NASDAQ:MLEC) has announced a transformational all-stock Business Combination Agreement with Bioceres Group and other entities. The deal involves Moolec issuing up to 87 million new shares and 5 million warrants to acquire Bioceres Group, Nutrecon , and Gentle Technologies Corp.
The combined entity will control a portfolio of over 800 patents and 550 product registrations, representing more than half a billion dollars in annual sales across 50+ countries. The transaction positions Moolec as a comprehensive agricultural technology company, integrating molecular farming, biological inputs, and climate-resilient seeds.
Key highlights include:
- Continued development of molecular farming products (Piggy Sooy™, GLASO™)
- Integration of biological agricultural solutions through Bioceres Group
- Expansion into R&D and CDMO services under Agrality® and Synbio Powerlabs®
- Development of emerging technologies in biomaterials and farm equipment
Moolec Science SA (NASDAQ:MLEC) has received a Nasdaq Staff Determination Letter on March 11, 2025, indicating non-compliance with listing requirements as its stock price remained below $1.00 for over 30 consecutive business days since September 10, 2024. The company is not eligible for a second 180-day compliance period due to not meeting the $5,000,000 minimum stockholders' equity requirement.
On March 13, 2025, Moolec appealed the determination and plans to present a compliance strategy involving a reverse share split. The appeal temporarily halts any delisting actions. The Board of Directors has resolved to convene an extraordinary shareholders meeting to vote on the reverse share split. Without securing an extension from the Hearings Panel or achieving compliance, the company's ordinary shares and warrants face potential delisting from Nasdaq.
Moolec Science SA (NASDAQ:MLEC) has received USDA approval for the first genetically modified pea in history. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) completed its Regulatory Status Review for Moolec's genetically engineered peas that produce iron through bovine meat proteins. This marks Moolec's third USDA-APHIS regulatory clearance in 18 months, following approvals for genetically engineered safflower and soybean.
The GE peas produce high yields of bovine myoglobin, boosting iron content and offering a plant-based iron source. This innovation has the potential to impact both the food ingredient market and the $65 billion pea industry. The approval validates Moolec's strategic approach and commitment to sustainable food production through science and innovation.
Moolec Science SA (NASDAQ:MLEC) reported its Business Update for Q4 FY2024 ended June 30, 2024. Key highlights include:
1. GLASO™: Secured an offtake agreement with a major global CPG food and pet food company and an R&D collaboration with Bunge. Significant advancements in upstream and downstream processes.
2. Piggy Sooy™: Field trials in three US locations progressing for product development, seed increase, and regulatory data gathering.
3. TSP Valorasoy™: Trials for enhanced Valorasoy 2.0 products showed encouraging results.
4. Financials: Revenue & other income of ~$6M for FY 2024, driven by soy protein ingredient business. Prudent cash burn in line with company growth.
The company highlighted the USDA-APHIS approval for PiggySooy™ as a pivotal moment in Molecular Farming. Moolec is preparing for the commercialization of GLASO™ and advancing its product pipeline.
Moolec Science SA (NASDAQ:MLEC), a science-based food ingredient company, has announced it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on October 2, 2024, before market open. The company will host a live Conference Call and webcast on the same day at 08:30 AM ET.
The call will feature CEO Gastón Paladini, CFO José López Lecube, and Chief Science Officer Amit Dhingra. It will include a presentation viewable during the webcast, with a replay and PDF version available afterwards on Moolec's Investor Relations website.
Participants can join via the provided Zoom link or dial-in numbers. The webinar ID is 915 9750 1131, with passcode 799765. International dial-in numbers are also available.
Moolec Science SA (NASDAQ:MLEC), a food ingredient company, received a Nasdaq Bid Price Letter due to its closing bid price falling below $1.00 for 30 consecutive business days. This violates Nasdaq Listing Rule 5550(a)(2). The company has until March 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, Moolec may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing requirements. Failure to comply could result in delisting. Moolec is committed to resolving the deficiency and maintaining its Nasdaq listing.
Moolec Science SA (NASDAQ:MLEC) has announced the upcoming harvest of its genetically engineered plant-grown products GLASO™ and Piggy Sooy™ in October 2024. The GLASO™ campaign in Idaho covers 600 acres and is expected to yield 300-400 tons of high-GLA safflower seeds. Moolec has secured an offtake agreement with a major global CPG company for GLASO™, targeting the US market in 2025. Piggy Sooy™ field trials are being conducted in Ohio, Missouri, and Iowa for product development, seed increase, and regulatory data gathering. Moolec recently obtained USDA-APHIS approval for Piggy Sooy™ cultivation, marking a significant milestone in Molecular Farming. The company aims to provide sustainable solutions in agriculture and biotechnology, with Piggy Sooy™ potentially producing pork meat proteins equivalent to 10 pigs per acre while reducing environmental impact.
FAQ
What is the current stock price of Moolec Science (MLEC)?
What is the market cap of Moolec Science (MLEC)?
